Loading
SP
Syros Pharmaceuticals, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 12 Sept 2024.
Syros Pharmaceuticals, Inc.: what insiders have been doing
Syros Pharmaceuticals, Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Nothing new has been filed by managers of Syros Pharmaceuticals, Inc. in twelve months, the latest record being from 4 December 2024.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
75
Thresholds
n/a
Buy Volume
n/a
4 ops. · all time
Sell Volume
€4,408
15 ops. · all time
Who traded when
BuySaleNancy A. Simonian2 sales
Conley Chee1 sale
David Roth1 sale
Gerald E. Quirk1 sale
Jason Haas1 sale
Kristin Stephens1 sale
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2023FY ended December 2023 · cache
US$0.00
Analyst consensus
4 analystsUS$4.00Target US$8.75(+8749900%)US$20.00
Income statement
RevenueUS$9.9M
EBITDA-US$157.2M-1582% margin
Net income-US$164.6M-1656.3% margin
Valuation
PER (forward)-0.0x
Beta1.33
Balance sheet & cash
Market capUS$2.7k
Total debtUS$62.1M
Free Cash Flow-US$110M
Profitability & ownership
ROE-777.0%
ROA-59.9%
% insiders0.1%
% institutions9.6%
Last declaration on 4 December 2024
Declarations75 total
37,070 shares@ €0.25629.2% of flowCommon StockSEC:0000950170-24-133338:0
134,713 shares@ €0.253233.1% of flowCommon StockSEC:0000950170-24-131591:0
12,099 shares@ US$0.19691.5% of flowCommon StockSEC:0000950170-24-129383:0
134,797 shares@ €0.189727.2% of flowCommon StockSEC:0000950170-24-129380:0
46,657 shares@ €0.2088100.0% of flowCommon StockSEC:0000950170-24-129381:0
137,803 shares@ €0.199635.6% of flowCommon StockSEC:0000950170-24-129378:0
36,133 shares@ €0.208934.6% of flowCommon StockSEC:0000950170-24-129384:0
17,000 sharesCommon StockSEC:0000950170-24-120866:0
18,875 sharesCommon StockSEC:0000950170-24-120872:0
40,125 sharesCommon StockSEC:0000950170-24-120874:0
18,875 sharesCommon StockSEC:0000950170-24-120869:0
17,000 sharesCommon StockSEC:0000950170-24-120863:0
10,000 sharesCommon StockSEC:0000950170-24-111603:0
2,667 sharesCommon StockSEC:0000950170-24-107863:0
2,667 sharesCommon StockSEC:0000950170-24-107862:0
35,363 shares@ €1.4058100.0% of flowCommon StockSEC:0000950170-24-105995:0
Canonical exit: 9 Dec 2024 (T+90)
50,000 shares@ €1.3658100.0% of flowCommon StockSEC:0000950170-24-105994:0
Canonical exit: 9 Dec 2024 (T+90)
34,837 shares@ €4.7813100.0% of flowCommon StockSEC:0000950170-24-080480:0
4,000 shares0Common StockSEC:0000950170-24-070705:0
4,000 shares0Common StockSEC:0000950170-24-070706:0
4,000 shares0Common StockSEC:0000950170-24-070714:0
4,000 shares0Common StockSEC:0000950170-24-070711:0
4,000 shares0Common StockSEC:0000950170-24-070713:0
4,000 shares0Common StockSEC:0000950170-24-070703:0
4,000 shares0Common StockSEC:0000950170-24-070708:0
25 of 75 declarations
About Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing novel therapies in oncology, with a historical emphasis on hematologic malignancies. The company was incorporated in 2011 and changed its name to Syros Pharmaceuticals, Inc. in August 2012. It is headquartered in Cambridge, Massachusetts, United States. Syros traded on the Nasdaq Global Select Market under the ticker SYRS, but in February 2025 the company announced a voluntary delisting from Nasdaq and deregistration with the SEC as part of an orderly wind-down of the business. For investors, that is a critical framing point: Syros remains a U.S. healthcare name, but its public-market and operating profile shifted materially in 2025. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf))
Operationally, Syros built its research platform around controlling gene expression, aiming to discover medicines for patient subsets defined by specific biological and genomic features. Its best-known clinical asset has been tamibarotene, an oral selective RARα agonist studied in higher-risk myelodysplastic syndrome patients with RARA overexpression. The company also developed additional pipeline assets, including SY-2101 and SY-5609; the latter is an oral, selective CDK7 inhibitor that entered clinical testing in select solid tumors. This makes Syros a classic specialty biotech: science-driven, highly R&D-intensive, and dependent on clinical validation rather than commercial revenues. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf))
Read moreShow less
From a competitive standpoint, Syros operated in a very crowded and capital-intensive oncology biotech landscape, where larger or better-funded peers often have broader pipelines, deeper cash resources, and stronger partnering leverage. Syros’ strategy was differentiated by precision oncology and gene-regulation biology, but the company’s development risk remained substantial. In February 2025, Syros disclosed that its SELECT-MDS-1 Phase 3 trial of tamibarotene plus azacitidine failed to meet its primary endpoint of complete response rate. The company linked that outcome to an event of default under its loan agreement with Oxford Finance and stated that it had agreed to operate as a wind-down business, limiting spending under an Oxford-approved budget. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf))
In geographic terms, Syros is a Massachusetts-based U.S. biotech with no meaningful commercial footprint to highlight; its presence has been centered in Cambridge and in clinical-development activities. Its recent history is best understood as a company moving from an innovation-led oncology platform to an orderly capital-preservation phase, rather than a near-term commercialization story. For French-speaking investors, Syros therefore fits the profile of a high-risk U.S. micro-/small-cap biotech on Nasdaq that has transitioned into delisting and wind-down mode. ([d1io3yog0oux5.cloudfront.net](https://d1io3yog0oux5.cloudfront.net/_d68c9e0bb36396b16cecd23a67cde8d6/syros/news/2025-02-28_Syros_Announces_Voluntary_Delisting_from_Nasdaq_313.pdf))
